Korro Bio, Inc. current report, 17 June 2021

Full document

Business Context and Reporting Period

This Form 8-K filing by Frequency Therapeutics, Inc. (trading symbol: FREQ) reports on the Annual Meeting of Stockholders held on June 17, 2021. The company is incorporated in Delaware and is classified as an emerging growth company. The filing details the voting results for director elections and the ratification of the independent auditor.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance events and does not contain financial performance data.

Material Changes and Voting Results

The meeting saw 24,218,539 shares present, representing approximately 70.8% of outstanding common stock. All proposals were approved:

  • Director Elections (Class II):
    • Cynthia L. Feldmann: Elected with 16,339,706 votes FOR, 0 AGAINST, and 402,507 WITHHELD.
    • Michael Huang: Elected with 12,559,976 votes FOR, 0 AGAINST, and 4,182,237 WITHHELD.
    • Joel S. Marcus: Elected with 6,342,371 votes FOR, 0 AGAINST, and 10,399,843 WITHHELD.
  • Auditor Ratification: RSM US LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2021, with 24,169,826 votes FOR, 13,120 AGAINST, and 35,592 ABSTAINED.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the reporting of shareholder vote outcomes.

Investor Verification Checklist

  • Verify the total number of shares outstanding as of the April 19, 2021 record date to contextualize the 70.8% attendance rate.
  • Review the Definitive Proxy Statement filed on April 29, 2021, for detailed biographies of the elected directors and the rationale for the auditor appointment.
  • Confirm the term length for the newly elected Class II directors, which extends until the 2024 Annual Meeting.
  • Check subsequent filings for financial data, as this 8-K contains no revenue or cash flow information.